Cargando…
A multicentre, open-label, phase-I/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib vs. sorafenib in European patients with advanced hepatocellular carcinoma
BACKGROUND: This multicentre, open-label, phase-I/randomised phase-II trial evaluated safety, pharmacokinetics, maximum-tolerated-dose (MTD) per dose-limiting toxicities (DLTs), and efficacy of nintedanib vs. sorafenib in European patients with unresectable advanced hepatocellular carcinoma (aHCC)....
Autores principales: | Palmer, D. H., Ma, Y. T., Peck-Radosavljevic, M., Ross, P., Graham, J., Fartoux, L., Deptala, A., Studeny, M., Schnell, D., Hocke, J., Loembé, A-B., Meyer, T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5943284/ https://www.ncbi.nlm.nih.gov/pubmed/29563636 http://dx.doi.org/10.1038/s41416-018-0051-8 |
Ejemplares similares
-
Pharmacokinetics of Nintedanib in Subjects With Hepatic Impairment
por: Marzin, Kristell, et al.
Publicado: (2017) -
Phase I study of nintedanib in Japanese patients with advanced hepatocellular carcinoma and liver impairment
por: Okusaka, Takuji, et al.
Publicado: (2016) -
Vascular effects, efficacy and safety of nintedanib in patients with advanced, refractory colorectal cancer: a prospective phase I subanalysis
por: Mross, Klaus, et al.
Publicado: (2014) -
Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib
por: Wind, Sven, et al.
Publicado: (2019) -
A randomised, phase II study of nintedanib or sunitinib in previously untreated patients with advanced renal cell cancer: 3-year results
por: Eisen, T, et al.
Publicado: (2015)